Reticulin accumulation in essential thrombocythemia: Prognostic significance and relationship to therapy

Journal of Clinical Oncology

Volumn 27, Issue 18, 2009, Pages 2991-2999

  Campbell, Peter J ^a   Bareford, David ^a   Erber, Wendy N ^a   Wilkins, Bridget S ^a   Wright, Penny ^a   Buck, Georgina ^a   Wheatley, Keith ^a   Harrison, Claire N ^a   Green, Anthony R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; HYDROXYUREA; JANUS KINASE 2; RETICULIN; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; HEMOGLOBIN; QUINAZOLINE DERIVATIVE;

ADULT; ARTERY THROMBOSIS; ARTICLE; BONE MARROW BIOPSY; CLINICAL FEATURE; CONTROLLED STUDY; FIBROSIS; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; BLEEDING; BLOOD; BONE MARROW; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METABOLISM; MYELOID METAPLASIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS;

BIOLOGICAL MARKERS; BONE MARROW; HEMOGLOBINS; HEMORRHAGE; HUMANS; HYDROXYUREA; LEUKOCYTE COUNT; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROSPECTIVE STUDIES; QUINAZOLINES; RETICULIN; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS;

EID: 67649933816     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.3174     Document Type: Article

References (22)

1. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061, 2005
2. James C, Ugo V, Le Couedic JP, et al: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148, 2005
3. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790, 2005
4. Levine RL, Loriaux M, Huntly BJ, et al: The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106:3377-3379, 2005
5. Thiele J, Kvasnicka HM: Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features-a clinicopathological study on 272 patients. Histol Histopathol 18:93-102, 2003
6. Wilkins BS, Erber WN, Bareford D, et al: Bone marrow pathology in essential thrombocythemia: Interobserver reliability and utility for identifying disease subtypes. Blood 111:60-70, 2008
7. Campbell PJ, Scott LM, Buck G, et al: Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 366:1945-1953, 2005
8. Wolanskyj AP, Lasho TL, Schwager SM, et al: JAK2 mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance. Br J Haematol 131:208-213, 2005
9. Antonioli E, Guglielmelli P, Pancrazzi A, et al: Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19:1847-1849, 2005
10. Pikman Y, Lee BH, Mercher T, et al: MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270, 2006
11. Pardanani AD, Levine RL, Lasho T, et al: MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood 108:3472-3476, 2006
12. Beer PA, Campbell PJ, Scott LM, et al: MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood 112:141-149, 2008
13. Vannucchi AM, Antonioli E, Guglielmelli P, et al: Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 112:844-847, 2008
14. Campbell PJ, Green AR: The myeloproliferative disorders. N Engl J Med 355:2452-2466, 2006
15. Murphy S, Peterson P, Iland H, et al: Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34:29-39, 1997
16. Harrison CN, Campbell PJ, Buck G, et al: Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33-45, 2005
17. Bauermeister BE: Quantification of bone marrow reticulin: A normal range. Am J Clin Pathol 56:24-31, 1971
18. Cnaan A, Laird NM, Slasor P: Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 16:2349-2380, 1997
19. Thiele J, Kvasnicka HM, Zankovich R, et al: Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica 85:1126-1134, 2000
20. Thiele J, Kvasnicka HM: Chronic myeloproliferative disorders with thrombocythemia: A comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 82:148-152, 2003
21. Hultdin M, Sundstrom G, Wahlin A, et al: Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Med Oncol 24:63-70, 2007
22. Storen EC, Tefferi A: Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 97:863-866, 2001